01 — What is it?
TB-500 is commonly described as a thymosin beta-4-related research peptide, but products sold under the TB-500 name are not necessarily identical to native thymosin β4. Human clinical evidence exists for thymosin β4 itself.
Database / Research Profiles / TB-500
RESEARCH PROFILE
TB-500
Research-market name associated with thymosin beta-4
Tissue repairHuman thymosin β4 evidence; TB-500 identity varies
EVIDENCE SNAPSHOTHUMAN THYMOSIN Β4 EVIDENCE; TB-500 IDENTITY VARIES
Do not equate a commercial TB-500 product with the clinical evidence for recombinant/native thymosin β4 without verifying structure and identity.
Research-first: This profile summarizes published evidence and regulatory context. It is educational reference material, not a diagnosis, treatment recommendation, or personalized dosing protocol.
02 — Research category
Tissue repair. Evidence strength is based on the availability and quality of human clinical data, not on popularity in the research-peptide market.
03 — Evidence map
Human evidence: YESPreclinical evidence: SUPPLEMENTALPersonal dosing protocol: NOT PROVIDED
Do not equate a commercial TB-500 product with the clinical evidence for recombinant/native thymosin β4 without verifying structure and identity.
04 — Mechanism / biology
TB-500 is commonly described as a thymosin beta-4-related research peptide, but products sold under the TB-500 name are not necessarily identical to native thymosin β4. Human clinical evidence exists for thymosin β4 itself.
05 — Safety & limitations
Safety depends on the exact molecule, formulation, route, dose, indication and study population. Research-market products may differ in identity, purity, sterility or stability from materials used in published trials. Absence of reported adverse events in a small study does not establish long-term safety.
06 — Regulatory context
Regulatory status varies by compound and jurisdiction. Where an approved product exists, its approval applies only to specified formulations and indications. Investigational or research-market status should not be presented as equivalent to approval.